For diabetes mellitus. Sold as Humalog Mix 75/25, Humalog Mix 50/50. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant (sold as Humalog Mix 75/25, Humalog Mix 50/50), first approved Dec 22, 1999, with 0 new uses approved and 0 published complete response letters.
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Insulin Lispro Protamine and Insulin Lispro Injection | To Be Discontinued | Sep 1, 2026 | Sep 1, 2026 |
| Dec 22, 1999 | Humalog Mix 75/25BLA 21017 · TYPE 3/4 | Lilly | 37 | Marketed |
| Dec 22, 1999 | Humalog Mix 50/50BLA 21018 · TYPE 3/4 | Lilly | 30 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA